# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA4682948 | B | Inhibition of IDO1/TDO in IFNgamma-stimulated human A172 cells assessed as reduction in kynurenine formation at 100 uM using L-tryptophan as substrate incubated for 48 hrs by microplate reader analysis relative to control | Homo sapiens | 1 | ALA4680135 | tissue-based format | Scientific Literature | |
2. | ALA4682949 | B | Inhibition of recombinant human IDO1 assessed as reduction in kynurenine formation using L-tryptophan as substrate incubated for 45 mins by microplate reader assay | Homo sapiens | 76 | ALA4680135 | single protein format | Scientific Literature | |
3. | ALA4682950 | B | Inhibition of recombinant human TDO assessed as reduction in kynurenine formation using L-tryptophan as substrate incubated for 45 mins by microplate reader assay | Homo sapiens | 75 | ALA4680135 | single protein format | Scientific Literature | |
4. | ALA4682951 | B | Inhibition of IDO1/TDO in IFNgamma-stimulated human A172 cells assessed as reduction in kynurenine formation at 50 uM using L-tryptophan as substrate incubated for 48 hrs by microplate reader analysis relative to control | Homo sapiens | 1 | ALA4680135 | tissue-based format | Scientific Literature | |
5. | ALA4682952 | B | Reversal of IDO1/TDO-mediated suppression of mouse T-lymphocyte proliferation assessed as increase in mytomycin C treated LLC cells stimulated T-cells proliferation at 10 uM incubated for 3 days by Cell Titer Glo luminescent cell viability assay | Mus musculus | 1 | ALA4680135 | cell-based format | Scientific Literature | |
6. | ALA4682953 | F | Antitumor activity against mouse B16F10 cells xenografted in C57BL6 mouse assessed as tumor growth inhibition at 50 mg/kg, po administered for 19 consecutive days relative to control | Mus musculus | 1 | ALA4680135 | organism-based format | Scientific Literature | |
7. | ALA4682954 | F | Antitumor activity against mouse B16F10 cells xenografted in C57BL/6 mouse assessed as tumor growth inhibition at 100 mg/kg, po administered for 19 consecutive days relative to control | Mus musculus | 1 | ALA4680135 | organism-based format | Scientific Literature | |
8. | ALA4682955 | T | Toxicity in C57BL/6 mouse xenografted with mouse B16F10 cells assessed as body weight loss at 50 to 100 mg/kg, po administered for 19 consecutive days | Mus musculus | 1 | ALA4680135 | organism-based format | Scientific Literature | |
9. | ALA5216253 | B | Inhibition of IDO1 (unknown origin) | Homo sapiens | 12 | ALA5214925 | single protein format | Scientific Literature | |
10. | ALA5216254 | B | Inhibition of TDO (unknown origin) | Homo sapiens | 7 | ALA5214925 | single protein format | Scientific Literature | |
11. | ALA5216258 | F | Antiproliferative activity against melanoma cells (unknown origin) subcutaneously xenografted in mouse model assessed as inhibition of cell growth rate at 50 mg/kg relative to control | Not specified | 1 | ALA5214925 | organism-based format | Scientific Literature | |
12. | ALA5216259 | F | Antiproliferative activity against melanoma cells (unknown origin) subcutaneously xenografted in mouse model assessed as inhibition of cell growth rate at 100 mg/kg relative to control | Not specified | 1 | ALA5214925 | organism-based format | Scientific Literature |